Dr. Schountz’s lab of the Center for Vector-borne Infectious Diseases (CVID) is interested in understanding immune responses of bats to bat-borne human pathogenic viruses that typically lead to apathogenic infections in the bats. Current areas of interest are H18N11 bat influenza A virus, coronaviruses (MERS-CoV, SARS-CoV-2), and paramyxoviruses. Most work in the lab focuses on bat-borne viruses using a unique breeding colony of Jamaican fruit bats as an animal model.
Active projects are funded by NIAID to develop a better understanding as to why bats can host such high impact human pathogens that cause no discernible disease in bats. Bats have a number of seemingly unusual immunological features about them, including a robust type I interferon response, little evidence of inflammation, and little evidence of affinity maturation that typically leads to high titered antibody responses. These unusual features have undoubtably shaped the genomes of bat viruses, and it may be that they also contribute to the highly pathogenic nature of bat-borne viruses in humans.
People
news and updates view all
To bat immunologists such as Tony Schountz, the level of virus shedding is intricately related to the so-called immunological détente between pathogens and their bat hosts. “It’s a relationship in which the virus and the host effectively say to each other, ‘If you don’t bother me, I won’t bother you,’” he says.
By closely studying infectious diseases in his colony, Dr. Tony Schountz provides expert information on the implications and future of bat virology and immunology in relation to the pandemic.
CSU researchers expanded their neurovirology work to include anti-inflammatory drug therapies for COVID-19. Colorado State University is one of a small number of universities where this research can take place.